Berger Larry L
Known title: EVP & CHIEF TECHNICAL OFFICERCIK: 0001433832
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength. Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.
Transaction History
| ROG | ▲ Buy | Grant | 1,427 | $0 | 5/6/2026 | View on chart |
| ROG | ▲ Buy | Grant | 2,760 | $0 | 5/5/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 10,858 | $1.7M | 2/26/2025 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 8,163 | $2.2M | 2/26/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 10,858 | $2.9M | 2/26/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 9,804 | $1.8M | 2/26/2025 | View on chart |
| ECL | ▲ Buy | Grant | 2,209 | $0 | 2/19/2025 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 692 | $183K | 2/19/2025 | View on chart |
| ROG | ▲ Buy | Grant | 1,500 | $0 | 5/2/2024 | View on chart |
| ECL | ▲ Buy | Grant | 2,606 | $0 | 2/21/2024 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 821 | $178K | 2/21/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 7,889 | $929K | 6/16/2023 | View on chart |
| ECL | ▲ Buy | Option Exercise | 13,819 | $1.9M | 6/16/2023 | View on chart |
| ECL | ▼ Sell | Open Market | 21,708 | $3.9M | 6/16/2023 | View on chart |
| ROG | ▲ Buy | Grant | 950 | $0 | 5/4/2023 | View on chart |
| ECL | ▼ Sell | Open Market | 4,404 | $718K | 3/3/2023 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 742 | $118K | 3/1/2023 | View on chart |
| ECL | ▲ Buy | Grant | 2,353 | $0 | 2/22/2023 | View on chart |
| ECL | ▼ Sell | Other | 8,027 | $1.4M | 4/28/2022 | View on chart |
| ECL | ▲ Buy | Grant | 2,606 | $0 | 2/23/2022 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 820 | $144K | 2/23/2022 | View on chart |
| ECL | ▼ Sell | Open Market | 5,948 | $1.4M | 11/9/2021 | View on chart |
| ECL | ▲ Buy | Option Exercise | 8,000 | $942K | 9/9/2021 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 5,652 | $1.3M | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.